Silence Therapeutics plc (SLN) stock
SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.81−0.01 (-0.05%)
Close on Nov 19, 2026Market cap $935.96MP/E –Yield –
Silence Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Silence Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$56.29M. For fiscal 2025 it was -$91.08M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$91.08M | – |
| FY2024 | Dec 31, 2024 | -$63.32M | – |
| FY2023 | Dec 31, 2023 | -$64.38M | – |
| FY2022 | Dec 31, 2022 | -$61.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$14.22M | – |
| Q2 FY2026 | Jun 30, 2026 | -$13.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.58M | – |
See a number that looks wrong?